These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22963903)

  • 1. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
    Ordóñez NG
    Hum Pathol; 2013 Jan; 44(1):1-19. PubMed ID: 22963903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.
    Ordóñez NG
    Hum Pathol; 2007 Jan; 38(1):1-16. PubMed ID: 17056092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
    Ordóñez NG; Sahin AA
    Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
    Ordóñez NG
    Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
    Bishop JA; Sharma R; Illei PB
    Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Suster S; Moran CA
    Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
    Ordóñez NG
    Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
    Ordóñez NG
    Hum Pathol; 2005 Apr; 36(4):372-80. PubMed ID: 15891998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
    Amatya VJ; Takeshima Y; Kohno H; Kushitani K; Yamada T; Morimoto C; Inai K
    Histopathology; 2009 Jul; 55(1):10-9. PubMed ID: 19614762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.
    Hecht JL; Pinkus JL; Weinstein LJ; Pinkus GS
    Am J Clin Pathol; 2001 Oct; 116(4):483-8. PubMed ID: 11601132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
    Galateau-Salle F
    Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
    Pu RT; Pang Y; Michael CW
    Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
    Takeshima Y; Amatya VJ; Kushitani K; Inai K
    Am J Clin Pathol; 2008 Nov; 130(5):771-9. PubMed ID: 18854270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.